The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.
The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.
The company said sales of its AlloMap molecular diagnostic test were negatively affected during the quarter because of reduced collections from an external vendor.
The firm believes the diagnostics industry has not done a good job of communicating the value of medical tests to payors.
By scrutinizing more than 30,000 samples over dozens of studies, the team is exploring the genetics of transplantation complications.
The company reported total revenues of $7.1 million for Q2 and also missed the consensus Wall Street estimate on the bottom line.
The molecular diagnostics firm beat the consensus Wall Street estimate on the top line but missed it on the bottom line.
Diaxonhit, the exclusive European distributor of AlloMap, has selected a laboratory at Strasbourg University Hospitals to perform all testing on the continent.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.